Skip to main content
Equibles
PLSE logo

PLSE · Pulse Biosciences, Inc. · Metrics

Track PLSE — free

Use PLSE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLSE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$53.02 +0.34 (+0.65%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$3.78B
Shares
71.32M
Volume · Oct 23 453.02K Avg daily vol (3M) 516.14K

PLSE metrics

85 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$53.02
Market cap
$3.78B

Price action

20 metrics
Price change (1W)
+19.3%
Price change (30D)
+2.7%
Price change (3M)
+75.4%
Price change (6M)
+130.3%
Price change (YTD)
+286.2%
Price change (1Y)
+204.8%
Trailing year
Price change (5Y)
+138.0%
52-week high
$55.20
52-week low
$12.66
Change from 52-week high
-3.9%
Change from 52-week low
+318.8%
Annualized volatility
88.4%
Annualized volatility (3M)
67.1%
Beta
2.1
RSI (14D)
57.5
Price vs SMA 50
+5.2%
Price vs SMA 200
+74.6%
Avg volume (3M)
516,141
Relative volume
0.9
Average dollar volume
$24.90M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
71.32M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3,105.4×
reciprocal yield 0.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
3,191.2×
reciprocal yield 0.0%
P / book
38.0
reciprocal yield 2.6%
FCF yield
-1.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
5,244.3×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
4,428.4×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
0.3%
Operating margin
-7,007.8%
Trailing 12 months
Net margin
-6,755.8%
Gross profit (TTM)
$3,000
Operating profit (TTM)
−$83.04M
Net income (TTM)
−$80.06M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-5,180.4%
Effective tax rate
0.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.03
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.03
Operating cash flow per diluted share (TTM)
$-1.65
Free cash flow per diluted share (TTM)
$-1.66
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$0.71
Stock compensation per diluted share (TTM)
$0.26
Book value per share
$1.19

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.19M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+25.5%
Year over year · more shares
Revenue CAGR (3Y)
-20.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-80.5%
Return on assets
-69.3%
Debt / equity
0.0
Current ratio
9.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$61.39M
Quick ratio
9.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$101.62M
Latest balance sheet
Cash & equivalents
$101.62M
Total assets
$115.56M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$61.10M
Capital expenditures (TTM)
$290,000
R&D (TTM)
$51.89M
SG&A (TTM)
$31.16M
Stock compensation (TTM)
$17.47M
R&D / revenue
4,378.6%
Stock compensation / revenue
1,474.4%

Ownership (13F)

9 metrics
13F filers
106
13F filer change QoQ
+10
Institutional ownership
15.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
5.6%
Private-fund adviser ownership
4.4%
Active holders' share change QoQ
+65.0%
Holder tenure
11.1
Price vs estimated holder cost
+37.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.6%

Short interest

3 metrics
Short interest
4.6%
Latest settlement · 5.6 days to cover
Days to cover
5.6d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
$199,937
Insider-sentiment score
79 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1625101 CUSIP 74587B101 13F (30d) 17 filings 17 filers Visit website Investor relations